title: [Applying Fuzheng Huayu Gantang comprehensive therapeutic program for treatment of post-hepatitis B liver cirrhosis complicated with glyco-metabolic abnormality].
abstract: OBJECTIVE
  To study the clinical effects of Fuzheng Huayu Gantang comprehensive therapeutic program (FHGP) on post-hepatitis B liver cirrhosis associated with glyco-metabolic abnormality (LCGA).
  
  
  METHODS
  The patients with LCGA enrolled in the randomized controlled clinical trial were assigned to 2 groups, the treated group (68 cases) and the control group (74 cases), they were treated respectively by FHGP and conventional TCM and Western medicine therapeutic program for 3 months. Indexes including fasting plasma glucose (FPG), 2 h postprandial plasma glucose (2 h PG), fasting insulin (FINS) were detected, homeostasis model assessment insulin resistance (HOMA-IR) was calculated, and the score of syndrome was recorded before and after treatment. Then the effects on syndrome and glyco-metabolic abnormality were evaluated through statistical analysis.
  
  
  RESULTS
  Level of 2 h PG after treatment was lowered in both groups (P < 0.01), but significant difference was found in the pre-treatment to post-treatment decrement of FPG and HOMA-IR between the two groups (P < 0.05). The syndrome improving rate and the total effective rate on glyco-metabolic abnormality in the treated group were significantly better than those in the control group respectively (85.3% vs 64.9% , P < 0.01; 80.9% vs 62.2%, P < 0.05).
  
  
  CONCLUSIONS
  FHGP has the capability to improve the syndrome and glyco-metabolic abnormality of patients with LCGA.
authors.affiliation: Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai.
authors.forename: Chang-Qing
authors.initials: CQ
authors.lastname: Zhao
authors.forename: Hong-Tu
authors.initials: HT
authors.lastname: Gu
authors.forename: Yang
authors.initials: Y
authors.lastname: Cheng
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003131:Combined Modality Therapy; D004358:Drug Therapy / Q000379:methods; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D007333:Insulin Resistance; D008103:Liver Cirrhosis / Q000209:etiology / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods*; D008875:Middle Aged; D008517:Phytotherapy / Q000379:methods; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose